Literature DB >> 26718703

Controversy and consent: achieving patient autonomy in thrombolysis for acute submassive pulmonary embolism.

Sarah Rachel Pywell1, Christopher Daniel Smith1, Piero Reynolds1.   

Abstract

Acute pulmonary embolism (PE) is associated with a wide variation in patient outcome ranging from completely asymptomatic to cardiac failure and death. This presents a challenge to clinicians in ensuring the correct treatment for individual patients is given and that adverse events secondary to treatment complications are minimised. The evidence for those with massive PEs and non-massive PEs is clear for and against the use of thrombolysis, respectively. However, in those with 'sub-massive' PE there is no clear consensus on whether there is a treatment benefit. We present the case of a patient who presented with a non-haemodynamically significant PE but with evidence of right ventricular dilatation, and discuss the difficulties in treatment decisions in such cases, including the ethical and legal principles of consent, and how clinicians might best allow their patients to make informed decisions when in clinical equipoise. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718703      PMCID: PMC4716263          DOI: 10.1136/bcr-2015-209390

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Authors:  Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

3.  Thrombolytic therapy for submassive pulmonary embolus? PRO viewpoint.

Authors:  Luke S Howard
Journal:  Thorax       Date:  2013-04-26       Impact factor: 9.139

4.  2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

Authors:  Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

5.  Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.

Authors:  P S Wells; D R Anderson; M Rodger; J S Ginsberg; C Kearon; M Gent; A G Turpie; J Bormanis; J Weitz; M Chamberlain; D Bowie; D Barnes; J Hirsh
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

Review 6.  Initial treatment of venous thromboembolism.

Authors:  Simon J McRae; Jeffrey S Ginsberg
Journal:  Circulation       Date:  2004-08-31       Impact factor: 29.690

7.  Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.

Authors:  Silvy Laporte; Patrick Mismetti; Hervé Décousus; Fernando Uresandi; Remedios Otero; Jose Luis Lobo; Manuel Monreal
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

8.  Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials.

Authors:  Susan Wan; Daniel J Quinlan; Giancarlo Agnelli; John W Eikelboom
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

Review 9.  Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.

Authors:  William R Bell
Journal:  Rev Cardiovasc Med       Date:  2002       Impact factor: 2.930

10.  Assessing capacity and obtaining consent for thrombolysis for acute stroke.

Authors:  Jonathan Akinsanya; Paul Diggory; Elizabeth Heitz; Valerie Jones
Journal:  Clin Med (Lond)       Date:  2009-06       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.